NASDAQ:APLM

Apollomics Q2 2026 Earnings Results & Report

Apollomics logo
$16.37 -0.08 (-0.49%)
As of 02:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Apollomics reported Q2 2026 earnings on November 6, 2026. The company reported EPS of -$2.02.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes

Apollomics EPS Results

Actual EPS
-$2.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Apollomics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Apollomics Q2 2026 Earnings FAQ

Apollomics (NASDAQ:APLM) reported earnings of -$2.02 per share for Q2 2026. The report was announced on Friday, November 6, 2026.

Apollomics Earnings Headlines

Apollomics Reports First-Half 2026 Financial Results
Apollomics Inc - Ordinary Shares - Class A
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
Apollomics Inc
Apollomics Inc. Class A
See More Apollomics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Apollomics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apollomics and other key companies, straight to your email.

About Apollomics

Apollomics (NASDAQ:APLM) is a clinical-stage biopharmaceutical company focused on developing medicines for cancer, with an emphasis on targeted therapies and immuno-oncology. The company has operated in the United States and China.

Its lead candidate, vebreltinib (APL-101), is an investigational, selective inhibitor of the MET protein being studied in cancers with alterations in the MET pathway, including certain lung cancers. Apollomics has also described additional investigational oncology candidates in its pipeline.

Apollomics’ drug candidates are in development and are not approved medicines. The company was founded in 2015; its programs are intended to address cancers for which existing treatment options may be limited.

View Apollomics Profile